132365-02-7Relevant academic research and scientific papers
HEPATITIS B ANTIVIRAL AGENTS
-
Paragraph 0278, (2016/12/12)
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: [in-line-formulae]X-A-Y-Z-L-R1??(I)[/in-line-formulae] which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
Paragraph 0451; 0452; 0453; 0576; 0577; 0578, (2015/07/22)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
Paragraph 0444; 0569, (2015/09/22)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
NOVEL COMPOUNDS
-
Paragraph 0515; 0516, (2013/06/26)
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
NOVEL COMPOUNDS
-
Paragraph 0442; 0443, (2013/06/27)
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA
-
Page/Page column 101, (2013/06/27)
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
Organocatalytic asymmetric synthesis of quinine and quinidine
Sarkar, Shaheen M.,Taira, Yuko,Nakano, Ayako,Takahashi, Keisuske,Ishihara, Jun,Hatakeyama, Susumi
supporting information; experimental part, p. 923 - 927 (2011/03/20)
Quinine and quinidine were synthesized by a highly enantio- and stereoselective approach starting from a proline-catalyzed asymmetric cycloaldolization of benzyl bis(2-formylethyl)carbamate which gave a 70:30 mixture of (3R,4R)-N-Cbz-3-hydroxymethyl-4-hydroxypiperidine (96% ee) and its 4S-epimer (92% ee) in 94% yield after in situ NaBH4 reduction.
